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Stem Cell Sources and Their Homing to Tumors
Stem cells are characterized by their capacity for self renewal and 
their ability to differentiate into specific cell types under the influ-
ence of their microenvironment. They are the natural sources of 
embriogenetic tissue generation and continuous regeneration 
throughout adult life. The embryonic stem cells originate from 
the inner cell mass (ICM) of the gastrula1 and form the three 
germ layers: endoderm, mesoderm and ectoderm, each commit-
ted to generating specified tissues of the forming body.2 Tissue 
specific stem cells, such as mesenchymal stem cells (mesoderm), 
hematopoietic stem cells (mesoderm) and neural stem cells 
(ectoderm), have been identified as present and active for virtu-
ally every bodily tissue, and are hierarchically situated between 
their germ layer progenitors and differentiated end organ tissues.2 
Embryonic stem cells display indefinite self renewal capacity due 
to high telomerase expression. In contrast, telomerase activity in 
adult stem cells seems to be lower, limiting their perpetuation 
capacity in the long run.3 Recently, pluripotent stem cells have 
been shown to be generated from murine fibroblasts4 as well as 
from several human organs, such as heart, skin5 and bone mar-
row.6 More recently, stem cells derived from dental pulp7 and 
menstrual blood8 have also been isolated and studied to under-
stand their potential applications in therapy. A number of differ-
ent stem cell types have been used for the delivery of therapeutics 
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Stem cells have inherent tumor trophic migratory properties 
and can serve as vehicles for delivering effective, targeted 
therapy to isolated tumors and metastatic disease, making 
them promising anti cancer agents. encapsulation of 
therapeutically engineered stem cells in hydrogels has been 
utilized to provide a physical barrier to protect the cells 
from hostile extrinsic factors and significantly improve the 
therapeutic efficacy of transplanted stem cells in different 
models of cancer. This review aims to discuss the potential 
of different stem cell types for cancer therapy, various 
engineered stem cell based therapies for cancer, stem cell 
encapsulation process and provide an in depth overview of 
current applications of therapeutic stem cell encapsulation in 
the highly malignant brain tumor, glioblastoma multiforme 
(GBM), as well as the prospects for their clinical translation.
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to treat various cancers. These include mesenchymal stem cells 
(MSC), neural stem cells (NSC), umbilical cord derived stem 
cells (UCB SC) and adipose derived stem cells (ASC). However, 
bone marrow derived MSC have been widely studied for cancer 
therapy.
A number of studies have shown that various stem cell types 
migrate to sites of injury, ischemia and tumor microenviron-
ments; and extensive studies have shown that migration of stem 
cells is dependent upon the different cytokine/receptor pairs 
SDF-1/CXCR4, SCF-c-Kit, HGF/c-Met, VEGF/VEGFR, 
PDGF/PDGFr, MCP-1/CCR2, and HMGB1/RAGE (reviewed 
in ref. 9). SDF-1/CXCR4 has been shown as the most promi-
nent cytokine/receptor pair. The importance of the interaction 
between secreted SDF 1 and cell surface CXCR4 for stem cell 
migration has been displayed by experiments in which the activ-
ity of either the receptor or the cytokine has been inhibited.10-12 
Recent studies on gene expression profiles of stem cells exposed 
to conditioned medium (CM) of various tumor cells, revealed 
the downregulation of matrix metalloproteinase 2 (MMP-2) and 
upregulation of CXCR4 in stem cells.13 This exposure to tumor 
cell CM-enhanced migration of MSC toward tumor cells, which 
was further confirmed by SDF-1 and MMP-2 inhibition studies. 
Another recent study has reported the involvement of a potent 
pro inflammatory cytokine, macrophage migration inhibitory 
factor (MIF) in stem cell migration. An activating antibody 
(CD74Ab) was employed in this study to examine the effect of 
one MIF receptor, CD74 (major histocompatibility complex class 
II associated invariant chain), on SC motility. Targeting CD74 to 
regulate migration and homing potentially may be a useful strat-
egy to improve the efficacy of a variety of SC therapies including 
cancers.14 A recent study suggested that bioactive lipids, sphingo-
sine-1-phosphate and ceramide-1 phosphate contribute directly 
toward the migratory properties of stem cells and also the pres-
ence of these priming factors leads to robust response of stem 
cells to very low SDF-1 gradients.15 Besides targeting the tumor 
main burden, different stem cell types have been shown to track 
tumor metastases and small intracranial microsatellite depos-
its of different tumor types. The stem cells have been shown to 
effectively treat these sites with either the factors they release, or 
in loco expression of tumoricidal transgenes that they have been 
engineered with.16-18 These findings provide a strong rationale for 
the development of therapies that capitalize on the tumoritropic 
properties of stem cells by engineering them into carriers for anti 
tumor therapy.
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were successfully employed as delivery vehicles 
to deliver interleukin-12, a therapeutic gene in 
the management of malignant glioma.28 In 
another study, human umbilical cord blood 
stem cells (UCBSCs) were engineered to 
express interleukin-21 (IL-21) and were shown 
to have therapeutic efficacy in mice bearing 
ovarian cancer xenografts. This study sug-
gested that the UCBSC-IL-21 therapy was 
safe and feasible in ovarian cancer therapy, 
and that the method would be a promising 
new strategy for clinical treatment of ovarian 
cancer.29
Interferons. Human bone marrow MSC 
secreting interferon IFNb has been proven 
to have success in diminishing a number of 
tumors such as melanoma,30 breast cancer31 
and lung metastases.32 In a recently published 
study, amniotic fluid derived mesenchymal 
stem cells (AF-MSCs) were isolated, investi-
gated for their tumor tropism and capability 
to transport interferon-b (IFNb) to the region 
of neoplasia in a bladder tumor model. A sig-
nificant inhibition of tumor growth as well 
as prolonged survival of mice was observed in the presence of 
AF- MSC-IFNb, thereby demonstrating the potential of engi-
neered AF-MSCs as anti cancer vehicles.33 In another study, adi-
pose tissue derived stem cells were engineered to secrete IFNb 
and were used in combination with the chemotherapeutic agent, 
cisplatin to demonstrate a marked reduction in tumor growth in 
a mouse model of melanoma.34 Yi et al., recently demonstrated 
that genetically engineered stem cells are capable of migrating 
to and effectively eliminating lung cancer cells. Using a gene 
directed enzyme pro drug therapy, wherein human neural stem 
cells (NSC) were engineered to express the suicide gene, cyto-
sine deaminase (CD) and also secrete IFNb, Yi and his col-
leagues found a marked reduction in the growth of lung cancer 
cells in culture upon treatment with the prodrug for CD, 5 
flourocytosine.35
Suicide gene therapy. The suicide gene therapeutic approach 
is based on the conversion of non toxic prodrugs into active 
anticancer agents via introduction of non mammalian or mam-
malian enzymes. One of the earliest suicide gene therapies 
demonstrated is the herpes simplex virus thymidine kinase 
(HSV-TK) Ganciclovir (GCV) system.36,37 HSV-TK is a viral 
enzyme that catalyzes the phosphorylation of nucleotide analogs 
such as antiviral drug GCV.38 The phosphorylated GCV then 
selectively kills cancer cells through a bystander effect via apop-
totic or non apoptotic mechanisms.39 In addition to this system, 
there have been several other suicide enzyme-prodrug systems 
including cytosine deaminase (CD)/5 fluorocytosine (5-FC),40,41 
cytochrome P450/cyclophosphamide,42 carboxypeptidase/chlo-
roethyl mesyloxyethyl-aminobenzoyl-glutamic acid (CMDA)43 
and carboxylesterase (CE)/CPT-11.44 When human NSC-line 
HB1.F3 carrying CD enzyme gene (F3.CD) was transplanted 
intracranially at distant sites from the tumor, NSC were shown 
The unmodified stem cells, particularly MSC, have been 
shown to have anti tumor effects both in vitro and in vivo in 
different mouse models of cancer. This is attributed to the fac-
tors released by MSCs that have antitumor properties; reducing 
the proliferation of glioma, melanoma, lung cancer, hepatoma 
and breast cancer cells.19-22 Human bone marrow derived MSC 
injected intravenously (i.v.) in a mouse model of Kaposi’s sarcoma 
were shown to home to sites of tumorigenesis and potently inhibit 
tumor growth.23 MSCs have also been shown to have anti angio-
genic effect both in vitro and in mouse models of melanoma.24 
Direct injection of MSC into subcutaneous melanoma bearing 
mice induced apoptosis and abrogated tumor growth.24
Stem cells based delivery of therapeutics. Different stem cell 
types have been genetically modified mainly to introduce and 
overexpress target exogenous genes for expression/secretion of 
a desired therapeutic factor for targeted treatment of different 
cancer types (Fig. 1).25 A number of studies have recently been 
published describing the successful use of stem cell based delivery 
of cytokines for the management of various human cancers. A 
few of the recent developments in this area are discussed below.
Interleukins. Stem cells have been efficiently employed for 
the delivery of interleukins in order to improve the anti cancer 
immune surveillance by activating cytotoxic lymphocytes and 
natural killer cells. A number of previously published studies 
demonstrated the efficacy of stem cell delivered interleukin(IL)s 
such as IL-2,20-IL-7[2], and IL-1826 in various tumors. However, 
MSC engineered to express interleukin (IL)-12 were recently 
shown to prevent metastasis into the lymph nodes and other 
internal organs as well as increased tumor cell apoptosis in mice 
bearing pre established metastases of melanoma, breast and hepa-
toma tumors.27 Furthermore, in a separate study, human umbili-
cal cord blood-derived mesenchymal stem cells (UCB-MSCs) 
Figure 1. Transgene strategies potentiating stem cells for tumor therapy. Tailored to 
the specific molecular profiles associated with individual tumor types, stem cells can 
be engineerd with a variety of different anti-tumor agents (adapted from ref. 25 with 
permission).
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Hyaluronic Acid Based Clinical Biomaterials
Hyaluronic acid (HA) is a non sulfated, linear polysaccharide 
with the repeating disaccharide,b-1,4-D-glucuronic acid-b-1,3- 
N-acetyl-D-glucosamine. HA is ubiquitous and highly hydrated 
polyanion and an essential component of the extracellular matrix 
(ECM); its structural and biological properties mediate cellular 
signaling, wound repair, morphogenesis and matrix organiza-
tion.59 Although HA and its derivatives have been clinically used 
in the past, it has become recognized as an important building 
block for the creation of new biomaterials for use in cell ther-
apy.60-62 Chemical modification of HA alters its material and 
biological properties,63 and targets three functional groups: the 
glucuronic acid carboxylic acid, the primary and secondary 
hydroxyl groups, and the N acetyl group (following deamida-
tion). The chemical, mechanical, and biological criteria for 
clinical and preclinical biomaterials are design constraints that 
must be incorporated into the biomaterial design.60,64 HA based 
synthetic extracellular matrices (sECMs) have been developed 
for use in drug evaluation and regenerative medicine.65 These 
sECMs were based on modification of the carboxylate groups of 
glycosaminoglycans (GAGs) and proteins such as gelatin using 
hydrazides containing disulfides.66,67 More importantly, in vivo 
injectable cell suspensions in the sECM macromonomers can 
be crosslinked with cytocompatible bifunctional polyethylene 
glycol (PEG) derived crosslinkers.68 The mechanical properties 
and rates of biodegradation could be altered by several varying 
parameters69: (1) molecular weight of starting HA employed; (2) 
percentage of thiol modification; (3) concentrations of thiolated 
HA and thiolated gelatin; (4) molecular weight of the crosslinker 
polyethylene glycol diacrylate (PEGDA); and (5) ratio of thiols 
to acrylates. Living hydrogels allow control of gel composition 
and mechanics, and permit incorporation of cells and a wide 
variety of small molecules, large molecules, nanoparticles, and 
microparticles.63
Role of HA Based Gels in Different Disease Models
Due to their ability to provide a physiologic environment that 
promotes stem cell survival while permitting easy in vivo trans-
plantation and cell retention, biodegradable HA based synthetic 
ECMs have been utilized in a variety of rodent models. A num-
ber of previous studies have shown that biodegradable sECM 
increase the viability of NSC and their differentiation into 
neurons in vitro.70 In models of intracerebral hypoxia ischemia 
and traumatic spinal cord injury, sECM acted as the necessary 
biomechanical substrate for endogenous neuro regeneration by 
increasing their stem cell viability and promoting differentiation 
into neurons.70-72 Subsequent studies have again highlighted the 
utility of biodegradable scaffolds in facilitating stem cell based 
therapy in the CNS.73,74 While sECM are ideally suited for 
retaining therapeutic stem cells at the site of repair as has been 
demonstrated by the previous studies.
A number of studies have been published recently, which have 
employed the hyaluronic acid based gels for developing novel 
therapies for various diseases. Ganesh et al. have developed a 
to migrate through normal tissue and selectively home to the 
glioblastoma tumor mass, which resulted in a significant reduc-
tion in tumor volume upon administration of prodrug 5-FC.45 
In a separate study, HB1.F3 human NSCs carrying peroxin 
(PEX) gene, were found to surround the invading brain tumor 
cell population, chase down infiltrating tumor cells, and also 
significantly kill tumor cells as demonstrated by a reduction in 
tumor volume.46 Bone marrow derived MSCs expressing the sui-
cide gene HSV TK, were demonstrated to potently eliminate 
prostate cancer cell mass both in culture and in vivo, in a study 
performed by Song et al.47 The different strategies that have been 
demonstrated so far reveal the promising potential of the com-
bination of stem cell based therapies and suicide gene strategies 
to combat tumors.
Pro-apoptotic proteins. The delivery of pro apoptotic proteins 
such as TRAIL (tumor necrosis factor related apoptosis induced 
ligand) via stem cells is a relatively new approach toward tumor 
cell killing. TRAIL is an endogenous member of the TNF ligand 
family that binds to its death domain containing receptors DR4 
and DR5 and induces apoptosis via activation of caspases, pref-
erentially in cancer cells while sparing most other cell types.48 A 
number of studies have shown that the therapeutic efficacy of 
different adult stem cell types, including MSC, engineered to 
express TRAIL in either cell lines or mouse models of colorectal 
carcinoma,49 gliomas,50-52 lung, breast, squamous and cervical 
cancer53 result in induction of apoptosis and a subsequent reduc-
tion of tumor cell viability. Previous work from our laboratory 
has focused on designing a secretable version of TRAIL that 
consists of fusion between the extracellular domain of TRAIL 
and the extracellular domain of the hFlt3 ligand which binds to 
the Flt3-tyrosine kinase receptor. The re engineered recombi-
nant protein named “secretable TRAIL” (S-TRAIL) is efficiently 
secreted into the producer cell’s immediate microenvironment 
and exhibits higher cytotoxicity on glioma cells than the native 
TRAIL protein.17,54,55
Encapsulated Stem Cells for Therapy
Cell encapsulation technology refers to immobilization of cells 
within biocompatible, semipermeable membranes. The encapsu-
lation of cells instead of therapeutic products, allows the delivery 
of molecules of interest for a longer period of time as cells release 
these molecules continuously. In addition, genetically engineered 
cells can be immobilized to express any desired protein in vivo 
without the modification of the host’s genome.56 Encapsulation 
of cells presents an important advantage as compared with 
encapsulation of proteins, as the latter allows a sustained and 
controlled delivery of therapeutic molecules at a constant rate 
giving rise to more physiological concentrations.56 Due to their 
ability to provide a physiologic environment that promotes cell 
survival and prevent immune response while permitting easy in 
vivo transplantation and cell retention, biodegradable hydrogels 
and synthetic extracellular matrix (sECM) to encapsulate stem 
cells have been utilized.57,58 A number of different biomaterials 
such as alginate, hyaluronic acid, agarose and other polymers 
have been used for encapsulation.
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novel hyaluronic acid based self assembling nanosystems wherein 
they have encapsulated siRNA targeting CD44 in these novel 
hyaluronic acid based systems to treat solid tumors.75 In another 
recent study, it was demonstrated that the addition of recombi-
nant gelatin to hyaluronic acid based gels makes them unique 
scaffolds that can be injected for soft tissue growth.76 Chang et 
al. in their recent study, have demonstrated the use of a novel 
hyaluronic acid blood biodegradable hydrogel, which offers a 
unique potential of transplanting stem cells into the myocar-
dium, thereby contributing to a better cardiac function following 
a myocardial infarction.77 Recent in vivo studies suggest consid-
erable potential for transplanted biodegradable scaffolds contain-
ing stem (and other neuronal) cells in models of degeneration 
and hypoxia ischemia.78 Encapsulating human MSC has been 
described as a novel hypo immunogenic platform for cellular 
therapy and also demonstrated this strategy to release hemopexin 
like protein (PEX) an anti angiogenic agent for the treatment of 
a glioma tumor.79
Role of HA-Based Gels in Developing Novel 
Therapies for Malignant Brain Tumors
Glioblastoma (GBM) is the most common primary brain tumor 
in adults with a very poor prognosis.80-82 Currently, treatment 
for GBM is maximal surgical tumor resection (debulking)83 
followed by radiation therapy, with concomitant and adjuvant 
chemotherapy.84,85 However, recurrence rates of GBM and the 
associated patient mortality are nearly 100%. Despite the numer-
ous pre clinical studies, most in vivo GBM models do not mimic 
the clinical scenario of surgical debulking and focus on treating 
solid intact intracranial tumors. Therefore, in light of the central 
role tumor resection plays in clinical GBM therapy, development 
and implementation of mouse models of GBM resection are a 
necessity.86 In a recent study, we have developed a mouse resec-
tion model of GBM in cranial windows using malignant GBM 
cells engineered with fluorescent and bioluminescent proteins, 
which allow real time visualization of both growth and resec-
tion of tumors in vivo thereby simulating the clinical scenario of 
GBM resection. While resection of the primary tumor mass has 
shown clinical benefit, adjuvant chemotherapy has provided lim-
ited additional benefit (Fig. 2A).80,84 One of the major impedi-
ments to the efficient delivery of many therapeutic molecules is 
the blood brain barrier (BBB)87 and vascular dysfunction in the 
tumor,88 which prevents many drugs from reaching brain tumor 
cells. One of the approaches to overcome the drug delivery prob-
lems to intracranial tumors is to develop onsite means to deliver 
novel tumor specific agents. There are a number of limitations 
to effectively test stem cell based therapeutic interventions in a 
mouse model of GBM resection, including developing methods 
to introduce stem cells into the resection cavity to prevent rapid 
“wash-out” of a significant number of cells by cerebrospinal fluid 
(CSF). Additionally, it is critical to allow efficient secretion of 
anti GBM therapies and retain the ability of stem cells to migrate 
from the resection cavity into the parenchyma toward invasive 
tumor deposits. Due to their ability to provide a physiologic envi-
ronment that promotes stem cell survival while permitting easy 
in vivo transplantation and cell retention, we utilized sECMs 
that are based on a thiol modified hyaluronic acid (HA) and a 
thiol reactive cross linker (polyethylene-glycol-diacrylate), which 
provides biocompatibility, physiological relevance, and customiz-
ability (Fig. 1).26
In our recent study, we first assessed the influence of sECMs 
on stem cell survival in vivo and showed that there was a signifi-
cant increase in cell viability in mice bearing sECM encapsulated 
NSC as compared with the non encapsulated NSC (Fig. 2). In 
order to follow migration of sECM encapsulated NSC, we used 
intravital imaging on mice bearing GBMs in a cranial window 
and implanted with mNSC GFP Rluc encapsulated in sECMs 1 
mm away from an established tumor. It was revealed that sECM 
encapsulated NSC migrate out of the sECMs and specifically 
home to tumors in the brain over a period of 4 d (Fig. 2). In 
order to assess the therapeutic potential of NSC expressing thera-
peutic proteins that specifically kill tumor cells, we engineered 
NSC to express secretable (S)-tumor necrosis factor related 
apoptosis inducing ligand (TRAIL). TRAIL is a cytotoxic agent 
that is known to induce apoptosis in about 50% of GBM 89,90 
We observed a significant reduction in GBM cell viability when 
NSC-S-TRAIL encapsulated in sECMs were placed in the cul-
ture dish containing TRAIL sensitive human GBM cells. Our in 
vitro studies thus revealed that sECM encapsulated engineered 
NSC survive longer in mice brains, migrate to tumors in the 
brain and induce apoptosis in cultured GBM cells (Fig. 2).
To assess survival of NSC encapsulated in sECMs in mouse 
model of GBM resection, we implanted NSC expressing a fusion 
of a fluorescent (GFP) and bioluminescent (Fluc) protein (NSC 
GFP Fluc) either in suspension or encapsulated in the resection 
cavity of U87 GBMs. sECM encapsulated NSC were retained 
in the tumor resection cavity at high local concentrations adja-
cent to the residual tumor cells and their survival in the tumor 
resection cavity over a period of 1 mo was significantly higher 
as compared with the non encapsulated NSC in the resection 
cavity (Fig. 2). When sECM encapsulated NSC S TRAIL were 
implanted intracranially in the tumor resection cavity to assess 
the therapeutic potential of sECM encapsulated NSC-S-TRAIL 
in mouse resection models of GBM, the sECM encapsulated 
NSC S TRAIL suppressed regrowth of residual tumor cells 
through 49 d post resection. Highlighting the survival benefit 
of this approach, 100% of mice treated with NSC-S-TRAIL 
encapsulated in sECM after GBM resection were alive 42 d post 
treatment as compared with the controls which showed a median 
survival of 14.5 d after GBM resection. Our studies thus revealed 
that sECM encapsulated therapeutic NSC are retained in the 
tumor resection cavity, kill residual GBM cells and result in sig-
nificantly increased survival of mice. Our studies on freshly iso-
lated primary GBM lines from GBM patients and human MSC 
expressing S-TRAIL more accurately recapitulate the clinical 
scenario of GBMs and show that sECM encapsulated engineered 
human MSC have therapeutic benefits against primary patient 
derived GBMs. These studies clearly reveal that sECM encapsu-
lated engineered stem cells are effective by way of increasing the 
concentration of therapeutic stem cells at the site of tumor resec-
tion to extend the drug exposure time to tumor cells.
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Prospects and Caveats on the Way to the Clinics
Encapsulating therapeutic stem cells provides numerous advan-
tages and helps overcome a number of caveats in the current 
cell based therapies. Stem cells have an incredible potential in 
developing novel targeted therapies for various diseases includ-
ing cancer. The evidence that stem cells have the potential to 
migrate efficiently to lesions, tumors or other sites of damage 
has led to the development of unique stem cell based therapeu-
tics which are gaining significant importance in today’s scien-
tific world. This has triggered the urge in various researchers 
to study and obtain a detailed understanding of these mecha-
nisms which thereby have led to the emergence of targeted 
therapeutics that are robust and effective. However, in spite of 
significant advances in this field, the translation of such thera-
pies from bench to bedside still remains a daunting task. The 
appropriate disease models that exactly mimic the clinical sce-
nario are very crucial to demonstrate the usefulness and appli-
cability of novel therapeutic approaches. Emerging technologies 
like the encapsulation strategy are much needed to supplement 
the cell transplantation therapeutics, and the incorporation of 
such strategies aid in better delivery and longer duration of the 
desired therapy and thereby boost the probability of the success 
of these proposed therapies. The use of clinically employed bio-
degradable hydrogels like the HA based gels for encapsulation 
of “armed” stem cells will not only have a great impact on thera-
peutic outcomes but will also make the translation of therapies 
into clinics a reality.
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Figure 2. Stem cells engineered to express S-TRaiL have therapeutic efficacy in mouse tumor model of GBM resection. (A) photomicrographs of 
mice bearing established u87-mcherry-Fluc GBM tumors in the cranial window that were injected with a blood pool agent, angioSense-750 before 
(top) and after (bottom) tumor resection. (B) Kaplan-Meier survival curves of mice with and without resected u87-mcherry-Fluc tumors. (C-G) Stem 
cell (Sc) (green) expressing a secretable in vivo marker, Ss-Rluc(o) or therapeutic S-TRaiL were encapsulated in secM and places in a culture dish 
containing u87-mcherry-Fluc tumor cells (red). photomicrographs of Sc at 8 h (C, E) and 24 h (D, F) and plot showing tumor cell viability (G). (H-J) 
Sc-GFp-Fluc in suspension or encapsulated in secM were implanted intracranially in the resection cavity of the mouse model of resection, injected 
with angiosense-750 i.v. and mice were imaged by intravital microscopy and by serial imaging. photomicrograph showing fluorescent images of secM 
encapsulated Sc-GFp-Fluc implanted in the resection cavity (H) and Sc (green) targeting residual GBM cells (red) indicated by arrows in a tumor resec-
tion cavity with leaky vasculature (blue) (I). (J) plot and representative figures of the relative mean Fluc signal intensity of Sc-GFp-Fluc in suspension 
or encapsulated in secMs placed in the GBM resection cavity. (K) Sc-S-TRaiL or Sc-GFp-Rluc encapsulated in secM or Sc-S-TRaiL in suspension were 
implanted intracranially in the tumor resection cavity and mice were followed for survival. Kaplan Meier survival curves are shown (adapted from ref. 
86 with permission).
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